On November 28, 2016 Zymeworks Inc., a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, initially focused on the treatment of cancer, reported that its abstract has been accepted for Poster Presentation at the 2016 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, being held from December 3-6, 2016 in San Diego, California (Press release, Zymeworks, NOV 28, 2016, View Source [SID1234516820]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Zymeworks will present at the following session:
Session Information: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I
Abstract Title: ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity
Date: December 3, 2016
Time: 5:30 p.m. – 7:30 p.m. PST
Location: San Diego Convention Center, Hall GH